Inclusion Criteria:

• Healthy male or female between 18 and 65 years of age inclusive.
•A female subject is eligible to participate if she is of either non-childbearing potential or child-bearing potential and agrees to use one of the contraception methods
•No co-morbid Psychiatric Disorders as defined using the Mini International
Neuropsychiatric Interview (M.I.N.I) scale.
•A 12-lead ECG at screening showed no abnormalities that in the opinion of the
Principal Investigator will compromise safety in this study.
-
• Body weight ≥ 50 kg and BMI within the range 19.0 – 29.9 kg/m2 (inclusive).
•Capable of giving written informed consent

Exclusion Criteria:

•As a result of any of the medical interview, physical examination or screening
investigations the Physician Responsible considers the subject unfit for the study.
•The subject has a history of a drug or other allergy which in the opinion of the
Physician Responsible contraindicates the participation in the study.
•Subjects with an unstable medical disorder or a disorder that would likely interfere
with the action, absorption, distribution, metabolism or excretion of orvepitant, may
pose a safety concern, or interfere with accurate assessment of safety.
•The subject has a current or recent (within six months) documented gastrointestinal
disease; a history of malabsorption, oesophageal reflux, or irritable bowel syndrome;
frequent (more than once a week) occurrence of heartburn, or any surgical
intervention (e.g. cholecystectomy) which would be expected to influence the
absorption of drugs.
•History of psychiatric illness
•Any history of a clinically significant abnormality of the neurological system
(including dementia and other cognitive disorders or significant head injury) or any
history of seizure (excluding febrile seizure).
•Subject is consuming alcool or tobacco
•Subject is positive to Hepatitis B, C or HIV

• Italy (click to view all sites in Italy)
• GSK Investigational Site
  Verona, Veneto, 37134; Completed;